Swiss insurers to reimburse Clinuvel’s Scenesse
27 April, 2012 by Dylan Bushell-EmblingTwo Swiss insurers have agreed to reimburse Scenesse, developed by Clinuvel Pharmaceuticals (ASX:CUV), as a treatment for erythropoietic protoporphyria.
Annual AusBiotech-GSK Student Excellence Awards open now
26 April, 2012 by AusBiotechThe annual AusBiotech-GSK Student Excellence Awards aim to recognise and encourage promising research students and to raise awareness of research translation and applications.
CPI figures show PBS safety net is working: Medicines Australia
24 April, 2012 by Dylan Bushell-EmblingA 14.1% spike in the pharmaceutical component of the CPI is not down to a price hike, but instead shows that the PBS safety net is fulfilling its purpose, Medicines Australia's CEO says.
Mao’s Last Dancer to speak at AusMedtech
24 April, 2012 by AusBiotechThe 2012 AusMedtech national conference to be held in less than three weeks will feature inspirational speaker Li Cunxin, well known to many as Mao’s Last Dancer, amidst the program of over 40 speakers and panel sessions.
Biota merger to open US markets and investment
23 April, 2012 by Tim DeanA merger between Biota and US-based Nabi Pharmaceuticals will see Biota delist from the ASX and list on the Nasdaq with the aim of improving investment and commercialisation opportunities.
Pharmaxis gets marketing nod for Bronchitol in EU
20 April, 2012 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has secured marketing approval from the EU for its flagship cystic fibrosis drug, Bronchitol.
Inaugural AusBiotech AEI & AusFoodtech networking event hits the mark
19 April, 2012 by AusBiotechThe inaugural AusBiotech AEI (Agricultural Environment and Industrial biotechnology) & AusFoodtech event attracted 70 attendees from around Australia, representing the food, agricultural, industrial and environmental sectors of biotechnology.
Coridon gears up for herpes vaccine trial
18 April, 2012 by Dylan Bushell-EmblingProspects for a herpes cure are closer with Coridon signing a deal covering technology used in its experimental herpes vaccine, which is set to enter human trials this year.
Mesoblast hits 50% enrolment for back pain trial
18 April, 2012 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has enrolled half the patients for a US trial of off the shelf stem cells to restore degenerated intervertebral discs.
Living Cell taps lead investigator for NTCELL trial
18 April, 2012 by Dylan Bushell-EmblingParkinson's expert Dr Barry Snow has agreed to become the lead investigator for a NZ trial of Living Cell Technologies' (ASX:LCT) NTCELL treatment candidate.
Osprey Medical completes $20m ASX IPO
18 April, 2012 by Dylan Bushell-EmblingUS-based medical device company Osprey Medical (ASX:OSP) has completed its $20m IPO on the ASX.
Australian biotechs bullish despite economy and policy concerns
18 April, 2012 by Tim DeanThe AusBiotech Biotechnology Industry Position Survey has found Australian biotechs are optimistic about growth despite concerns over the economic and political environment.
Application for registration under the R&D Tax Incentive
17 April, 2012 by AusBiotechAusIndustry has launched a new publication outlining what will be required when businesses commence registering for the R&D Tax Incentive from 1 July 2012.
Pharmaxis asthma treatment found safe, but is it effective?
17 April, 2012 by Tim DeanA phase IIa trial of Pharmaxis’ (ASX:PXS) experimental allergic asthma drug, ASM8, has been shown safe, but more trials will be required to demonstrate efficacy.
vivoPharm buys RMIT's toxicology business
13 April, 2012 by Dylan Bushell-EmblingRMIT will sell its toxicology testing unit, RDDT, to vivoPharm Technologies in exchange for a 20% stake in the contract research organisation (CRO).
